Every 10-Q that Tango Therapeutics Inc (TNGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TNGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNGX filings page.
Tango Therapeutics reported a larger net loss as it shifts from collaboration funding to equity capital while advancing its oncology pipeline. For the quarter ended June 30, 2026, net loss was $55.3 million versus $38.9 million a year earlier, with no collaboration revenue following the 2025 truncation of its Gilead research agreement.
Research and development expense rose to $37.2 million, driven by vopimetostat and TNG456 trials, while general and administrative expense nearly doubled to $22.6 million, largely from higher stock-based compensation. A June 2026 equity offering and at-the-market sales lifted cash, cash equivalents and marketable securities to about $1.0 billion, which the company expects will fund operations for at least 12 months.
Clinically, vopimetostat combinations showed encouraging early data in MTAP-deleted, RAS-mutant cancers, including high objective response and disease control rates in pancreatic and lung cohorts, and the company plans a Phase 3 trial in frontline pancreatic cancer. Tango is deprioritizing TNG260, TNG961 and has stopped new enrollment in TNG908 to focus resources on its PRMT5 franchise.
Tango Therapeutics, Inc. reported first-quarter 2026 results showing no collaboration revenue, compared with $5.4M a year earlier, after the earlier truncation of its Gilead research collaboration. Research and development expense was $33.5M, down from $36.4M, mainly from lower spend on deprioritized programs, while general and administrative expense rose to $15.2M from $11.5M on higher personnel and stock-based compensation.
The company recorded a net loss of $45.5M (net loss per share $0.32) versus $39.9M (net loss per share $0.36) a year ago. Cash, cash equivalents and marketable securities totaled $379.8M as of March 31, 2026, and management expects this to fund operations into 2028.
During the quarter, Tango raised $64.4M in gross proceeds via its at-the-market stock offering, issuing 5,148,151 shares, and also generated $17.6M from stock option exercises. The company is prioritizing its MTAP-deleted selective PRMT5 pipeline, advancing vopimetostat and TNG456, while deprioritizing TNG260 and TNG961.
Tango Therapeutics (TNGX) reported a profitable Q3 on collaboration revenue tied to its Gilead partnership. Total revenue was $53.811 million, primarily from recognizing $53.8 million after the research term was mutually truncated, leading to operating income of $14.1 million and net income of $15.9 million (diluted EPS $0.13). By comparison, Q3 2024 revenue was $11.607 million with a net loss.
Year-to-date, revenue reached $62.384 million, with a net loss of $62.845 million reflecting R&D and G&A spend as development continues. Cash, cash equivalents and marketable securities were $152.8 million as of September 30, 2025. In October, the company closed an underwritten offering and concurrent private placement for $212.0 million in net proceeds, and expects a cash runway into 2028.
Pipeline updates include vopimetostat (PRMT5 inhibitor) with encouraging Phase 1/2 data: across 94 tumor-evaluable MTAP-deleted patients, ORR was 27% and mPFS 6.4 months; in second-line pancreatic cancer, mPFS was 7.2 months and ORR 25% (n=8), supporting a planned pivotal study. A histology-selective cohort showed ORR 49% and mPFS 9.1 months. TNG456 began dose escalation in GBM-focused MTAP-deleted tumors, and TNG260 reached an 80 mg QD MTD with early signals in a defined NSCLC subset.